Editorial: radiosurgery and atypical meningiomas.

[1]  A. von Deimling,et al.  Long-term outcome after radiotherapy in patients with atypical and malignant meningiomas--clinical results in 85 patients treated in a single institution leading to optimized guidelines for early radiation therapy. , 2012, International journal of radiation oncology, biology, physics.

[2]  I. Yang,et al.  The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments. , 2011, Neurosurgical focus.

[3]  A. Unterberg,et al.  Treatment of patients with atypical meningiomas Simpson grade 4 and 5 with a carbon ion boost in combination with postoperative photon radiotherapy: The MARCIE Trial , 2010, BMC Cancer.

[4]  M. Berger,et al.  The relevance of Simpson Grade I and II resection in modern neurosurgical treatment of World Health Organization Grade I meningiomas. , 2010, Journal of neurosurgery.

[5]  Arie Perry,et al.  Pathological classification and molecular genetics of meningiomas , 2010, Journal of Neuro-Oncology.

[6]  M. Gilbert,et al.  Intracranial meningiomas of atypical (WHO grade II) histology , 2010, Journal of Neuro-Oncology.

[7]  J. Sheehan,et al.  Stereotactic radiosurgery for WHO grade I meningiomas , 2010, Journal of Neuro-Oncology.

[8]  M. Berger,et al.  Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas. , 2010, Journal of neurosurgery.

[9]  A. von Deimling,et al.  Carbon ion radiation therapy for high-risk meningiomas. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  Susan M. Chang,et al.  Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). , 2009, Neuro-oncology.

[11]  Pascal Pommier,et al.  Combined proton and photon conformal radiotherapy for intracranial atypical and malignant meningioma. , 2009, International journal of radiation oncology, biology, physics.

[12]  W. Curry,et al.  LONG‐TERM RECURRENCE RATES OF ATYPICAL MENINGIOMAS AFTER GROSS TOTAL RESECTION WITH OR WITHOUT POSTOPERATIVE ADJUVANT RADIATION , 2009, Neurosurgery.

[13]  R. Mirimanoff,et al.  Atypical and malignant meningioma: outcome and prognostic factors in 119 irradiated patients. A multicenter, retrospective study of the Rare Cancer Network. , 2007, International journal of radiation oncology, biology, physics.

[14]  Peter J Park,et al.  Specific genes expressed in association with progesterone receptors in meningioma. , 2008, Cancer research.

[15]  Jordi Bruna,et al.  Ki‐67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma , 2007, Neuropathology : official journal of the Japanese Society of Neuropathology.

[16]  C. Russell,et al.  Long-Term Administration of Mifepristone (RU486): Clinical Tolerance During Extended Treatment of Meningioma , 2006, Cancer investigation.

[17]  P. Black,et al.  Epidemiology of intracranial meningioma. , 2005, Neurosurgery.

[18]  I. Whittle,et al.  The accuracy of meningioma grading: a 10‐year retrospective audit , 2005, Neuropathology and applied neurobiology.

[19]  M. Weiss,et al.  Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma , 1990, Journal of Neuro-Oncology.

[20]  K. Sugiyama,et al.  Antitumor effects of antiprogesterones on human meningioma cells in vitro and in vivo. , 1994, Journal of neurosurgery.